Pemvidutide vs Survodutide
Both GLP-1/glucagon dual agonists have biopsy-based MASH data; compare endpoints carefully because study populations, fibrosis stages, doses and timepoints differ.
| Attribute | Pemvidutide | Survodutide |
|---|---|---|
| Human evidence | Randomized Phase 2 obesity and MASH studies show weight-loss, liver-fat and MASH-resolution signals. The global PERFORMA Phase 3 MASH programme is active; pemvidutide remains investigational. | Published Phase 3 SYNCHRONIZE-1 evidence now shows significant weight loss in adults with obesity, alongside late-stage MASLD/MASH evidence. Survodutide remains investigational. |
| Research focus | Obesity, MASLD, MASH, alcohol-related liver disease, cardiometabolic risk | Obesity, MASH, liver fibrosis, cardiovascular outcomes |
| Regulatory status | Investigational. FDA granted Breakthrough Therapy Designation for MASH based on early clinical evidence; this is not marketing approval. | Investigational; no general marketing authorisation for obesity or MASH identified in the reviewed jurisdictions. |
| Route / formulation | Trial-grade once-weekly subcutaneous product; Breakthrough Therapy designation must not be presented as FDA approval. | Evidence is from trial-grade once-weekly subcutaneous product with protocol-driven escalation. |
Why these are compared
These compounds appear in the mash / metabolic liver disease evidence landscape, but they are not interchangeable. Pemvidutide is dual glp-1 receptor / glucagon receptor agonist peptide studied in obesity, masld, mash, alcohol-related liver disease, cardiometabolic risk; Survodutide is dual glucagon receptor / glp-1 receptor agonist peptide studied in obesity, mash, liver fibrosis, cardiovascular outcomes. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Pemvidutide: Phase 3 MASH development underway / investigational.
Survodutide: Published Phase 3 human evidence; investigational.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
No direct head-to-head trial identified. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.